Vancouver, British Columbia – TheNewswire – October 22, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to announce the first shipping container of NATERA Plant Based Foods has arrived from Australia. In anticipation of demand, a second shipping container has been processed and is on route toContinue reading “Naturally Splendid Receives First Container of NATERA Plant Based Foods”
Tag Archives: investing in Naturally Splendid Enterprises Ltd
Naturally Splendid Responds to Health Canada’s Information Request Notice
Vancouver, British Columbia – TheNewswire – October 16, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) has responded through their joint venture Plasm Pharmaceutical (“Plasm”) to Health Canada’s Information Request Notice (“IRN”). The questions as posed by Health Canada are considered a formality as Plasm Pharmaceutical, continues to prepare for aContinue reading “Naturally Splendid Responds to Health Canada’s Information Request Notice”
Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial
– TheNewswire – August 10, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) advises that subsequent to Heath Canada issuing a No Objection Letter, they have requested specific protocol details regarding the Clinical Trial Application for CavaltinibTM, the target drug of the proposed joint venture with Biologic Pharmaceutical Research, before the trial may commence.Continue reading “Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial”
Health Canada Grants No Objection Letter to Proceed with COVID-19 Phase 2 Clinical Trial
– July 29, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that the Company’s phase 2 clinical trial, as per its proposed joint venture with Biologic Pharmamedical Research for Cavaltinib(TM) (See Company news release, May 15, 2020.), has been approved for a COVID-19 clinical trial by Health Canada. The NoContinue reading “Health Canada Grants No Objection Letter to Proceed with COVID-19 Phase 2 Clinical Trial”
